Schering Corporation

Dendreon Corporation

Merck Sharp + Dohme Corp.

Other

Pharmacopeia Inc.

Merck Canada Inc.

Patrick A Pinto

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Richard William Versace

F George Njoroge

Srikanth Venkatraman

Anil K Saksena

Frank W Bennett

Kevin X Chen

Stephane L Bogen

Ashok Arasappan

Raymond G Lovey

Yi-Tsung Liu

Odile Esther Levy

Tin-Yau Chan

Russell E Pike

Marguerita S Lim-Wilby

Edwin Jao

Haiyan Wang

Tejal Parekh

Scott Jeffrey Kemp

Bama Santhanam

Zhaoning Zhu

Bancha Vibulbhan

Wanli Wu

Susan Y Tamura

Francisco Velazquez

Yuhua Huang

Henry A Vaccaro

Jinping L McCormick

Jinping L Mc Cormick

Siska Hendrata

Joseph A Kozlowski

Stuart B Rosenblum

Qingbei Zeng

Oleg B Selyutin

Yueheng Jiang

Stephen J Gavalas

John J Baldwin

Neng-Yang Shih

Ronald J Doll

Ge Li

Samuel Chackalamannil

Brian Alexander McKittrick

Timothy J Guzi

Duane A Burnett

Yongxin Han

Hubert B Josien

Alan B Cooper

Yan Xia

Dinanath F Rane

Zhuyan Guo

Jesse K Wong

Santhosh Francis Neelamkavil

Jing Su

Terence Kevin Brunck

Kartik M Keertikar

Charles A Lesburg

Carmen S Alvarez

Mariappan Chelliah

Linda Brockunier

Shouwu Miao

Latha G Nair

Unmesh G Shah

Ray Anthony James

Mousumi Sannigrahi

Jagdish A Desai

Anilkumar G Nair

Martin C Clasby

Gopinadhan N Anilkumar

Jose S Duca

Chia-Yu Huang

James J-s Wang

Thomas A Bara

Sathesh P Bhat

Austin Chen

Hugh Y Zhu

Henry M Vaccaro

Duan Liu

Keith P Minor

Murali Rajagopalan

Dipshikha Biswas

Haiyan Pu

Weiying Yang

Charles Jayne

Karen M Marcantonio

Li Wang

George F Njoroge

Robert Palermo

Boris Feld

Srinkanth Venkatraman

Vince J Colandrea

Hsueh-Cheng Huang

Thomas Bara

Brian Mckittrick

Unmesh Shah

Duane Burnette

Mariappan V Cheliah

Martin Clasby

Dipshika Biswas

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. 

Tricyclic indole derivatives and methods of use thereof

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

2,3-substituted indole derivatives for treating viral infections

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: wherein Z', L&#x2032;, M&#x2032;, R, X and D are defined herein.

Macrocyclic inhibitors of hepatitis C virus NS3-serine protease

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Farnesyl protein transferase inhibitors as antitumor agents

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

Compounds of the following formula useful for inhibiting Ras function and therefore inhibiting or treating the abnormal growth of cells are disclosed: ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein: R and R.sup.2 are halo;

Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl

The disclosed invention is compounds represented by the formula ##STR1## and pharmacetically acceptable acid salts thereof, wherein each Z is independently tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, lower alkoxy, phenoxy, nitrile, nitro, phenylsulfonyl, loweralkyl-sulfonyl, oxazol-2-yl, lower alkanoyl, benzoyl, lower alkoxycarbonyl, lower alkyl, lower alkylthio, phenyl, phenylaminothiocarbonyl, or lower alkylaminothiocarbonyl, hydroxyiminoloweralkyl hydroxyloweralkyl or carbonyl; or 4 or 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining member of the ring being at least one carbon, and optionally sulfur or oxygen, X and Y are each independently a bond, ##STR2## each Q is independently a divalent substituted or unsubstituted, straight or branched chain lower alkanediyl, lower alkanediyl-cycloalkanediyl-lower alkanediyl, lower alkenediyl, lower alkynediyl, phenylene, dihydrofurandiyl, loweralkanediyl-dihydrofurandiyl-loweralkanediyl, tetrahydrofurandiyl, tetrahydropyrandiyl, loweralkanediyl-tetrahydropyrandiyl-loweralkanediyl or, loweralkanediyl-tetrahydrofurandiyl-loweralkanediyl; W is a monovalent substituted or unsubstituted aryl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, with the proviso that W cannot be substituted or unsubstituted isoxazolyl, and with the further proviso that when Z is 2-chloro-4-methoxyphenyl, X is --O--, Q is C.sub.5 -C.sub.7 alkanediyl and Y is a bond, W is not imidazolyl substituted at positions 2, 4 and 5 with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyloweralkyl, nitro, loweralkoxycarbonyl, lower alkyl and amino methylene; W' is divale W. The compound is have antiviral activity, antiinflammatory activity and are PAF inhibitors.

Pharmaceutically active compounds

Orally active antiviral compounds

Growing community of inventors

Mine Hill, NJ, United States of America

Patrick A Pinto